MENLO PARK, Calif., Dec. 18, 2014 (GLOBE NEWSWIRE) -- Intersect ENT, Inc. (Nasdaq:XENT), a company dedicated to improving the quality of life for patients with ear, nose and throat conditions, today announced that management is scheduled to present an overview of the company's business, including certain preliminary 2014 results and 2015 outlook, at the J.P. Morgan 33rd Annual Conference at the Westin St. Francis Hotel in San Francisco, Calif., on Tuesday, January 13, 2015 at 10:00 a.m. PT/1 p.m. ET.
A live webcast of the presentation will be available online from the Investor Relations page of the Company's website at http://www.intersectENT.com. The webcast replay of the presentation will begin approximately one hour after the conclusion of the live presentation and will be available for approximately one month.
About Intersect ENT
Intersect ENT, Inc. is dedicated to improving the quality of life for patients with ear, nose and throat conditions. The company markets the first and only drug-eluting sinus implants, PROPEL and PROPEL mini, which are clinically proven to improve surgical outcomes for patients with chronic sinusitis. The products release an advanced steroid with anti-inflammatory properties directly into the sinus lining, then dissolve, maintaining the open passages created in ethmoid sinus surgery. In addition, Intersect ENT is pursuing clinical trials designed to support expanded indications and to assess two new investigational drug-eluting implants to provide ENT physicians with additional options to treat patients with chronic sinusitis less invasively and more cost effectively. Chronic sinusitis is an inflammatory condition leading to debilitating symptoms and chronic infections, and is one of the most costly conditions to U.S. employers. To learn more about Intersect ENT, please visit www.intersectENT.com.